Sonnet BioTherapeutics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Technology
    • Overview
    • Platform
    • Strategy
    • Progress
    • Publications
  • Pipeline
    • Overview
    • Clinical Trials
  • Partnering
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Jan 19, 2023 8:00am EST

Sonnet BioTherapeutics Announces Pharmacokinetic and Pharmacodynamic Data in a Phase 1 Dose-Escalation Trial of SON-1010

Jan 09, 2023 8:00am EST

Sonnet BioTherapeutics Announces a Collaboration with Roche for the Clinical Evaluation of SON-1010 with atezolizumab in Ovarian Cancer

Dec 15, 2022 4:05pm EST

Sonnet BioTherapeutics Provides Fiscal Year 2022 Business and Financial Update

Nov 02, 2022 8:00am EDT

Sonnet BioTherapeutics Announces Interim Data in Two Phase 1 Dose-Escalation Trials of SON-1010

Nov 01, 2022 4:05pm EDT

Sonnet BioTherapeutics Announces Webcast to Discuss Interim Data from the Company’s Phase 1 Dose-Escalation Trials of SON-1010 on November 2, 2022

Oct 31, 2022 7:30am EDT

Sonnet BioTherapeutics Announces an Agreement with Janssen for the Evaluation of Three Sonnet Product Candidates

Oct 04, 2022 8:00am EDT

Sonnet BioTherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 26, 2022 8:00am EDT

Sonnet BioTherapeutics Appoints Ms. Lori McNeill to the Board of Directors and Formalizes the Company's Business Advisory Committee

Sep 21, 2022 8:00am EDT

Sonnet BioTherapeutics Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010

Sep 16, 2022 8:30am EDT

Sonnet BioTherapeutics Announces 1-for-14 Reverse Stock Split

RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
Next
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
© 2023 Sonnet BioTherapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap